Senses Disorder TRIZ Cases

Lactam compounds suppress apoptosis in corneal epithelial cells, increasing lacrimal fluid and mucin production to resolve insufficient therapeutic effects.

TEMPO compounds scavenge free radicals to protect cellular structures, reducing oxidative stress and delaying age-related degenerative disorders.

Recombinant adeno-associated virus vectors deliver therapeutic antibody genes to ocular tissues for sustained local expression.

Replication-deficient adenoviral vector delivers human atonal homolog-1 to generate sensory hair cells, addressing permanent relief needs for hearing loss.

Optimizing pH to 4.8-6.5 maintains stability at high concentrations, reducing viscosity and aggregation for safer TAO treatment.

A composition of vitamins A, C, E, magnesium, and optional withanolide or resveratrol increases inner ear blood flow.

Identified AARS protein fragments enable novel biotherapeutic and diagnostic applications beyond canonical translation functions.

A selective Syk kinase inhibitor compound achieves potent enzyme inhibition.

Formula I compounds boost telomerase activity in cells despite oral bioavailability limits.

Dopamine beta-hydroxylase inhibitors regulate catecholamine synthesis to control autoimmune disease activity while minimizing adverse effects.

Citric acid eye drops dissolve aggregated lens proteins to restore transparency, addressing cataract surgical risks without invasive intervention.

Intravenous LPC-DHA formulations bypass peripheral hydrolysis and liver metabolism, delivering omega-3 fatty acids directly across the blood-brain barrier.

Monoclonal antibody binds properdin N terminus to block C3b interaction and inhibit the alternative complement pathway.

Human monoclonal antibodies neutralize hGM-CSF bioactivity, resolving immunogenicity and affinity trade-offs.

Tricyclic pyrido-carboxamide derivatives target Rho kinase to overcome drug resistance in cardiovascular treatments.

Acetone-water solvent crystallization yields canagliflozin Form IV with improved powder flowability, eliminating static electricity issues from small particles.

Novel carboxamide compounds selectively inhibit calpain enzymes through specific molecular structures, minimizing interference with other cysteine proteases.

Segmented nitric oxide releasing steroid compounds deliver prolonged vasodilator activity while reducing cardiac frequency modifications in ocular treatments.

Small molecule inhibitors block alpha-synuclein aggregation and neuroinflammation pathways to treat Gaucher and Parkinson diseases.

Formula I through IV compounds inhibit store-operated calcium channels, reducing cytokine release for autoimmune treatment.

Administering AMPK and PTEN activators to inhibit vascular tube formation and leakage in ocular neovascularization.

Benzonitrile derivatives inhibit TBK1 and IKKε kinases, resolving the lack of effective inhibitors for cancer and inflammatory diseases.

Oxysterol derivatives address inadequate therapeutic efficacy for broad NMDA-mediated disorders by acting as positive or negative allosteric modulators.

Electrolysis-driven active valve regulates fluid flow to manage intraocular pressure fluctuations and prevent fibrosis.

Pirfenidone capsules incorporating povidone optimize T max and AUC values, addressing insufficient therapeutic action in fibrotic conditions.

Q64R and M86Y mutations in CRIg increase C3b binding affinity thirty-fold, reducing required therapeutic concentrations.

Formula I compounds inhibit protein kinase C to treat diseases mediated by PKC activity.

Human antibodies bind IL-13Rα1 with high affinity to inhibit receptor activity while reducing immunogenicity in asthma treatment.

Specific amino acid substitutions in antibody variable domains resolve stability and yield trade-offs for multi-antigen binding.

Persistent release microspheres deliver agonists to ischemic regions.

A decellularized corneal stroma scaffold supports seeded endothelial cells to restore the corneal layer.

An adeno-associated viral vector delivers an abbreviated human RPGR cDNA to restore photoreceptor function.

Small molecule paxillin inhibitors modulate cellular adhesion and signaling pathways to treat ocular diseases.

Nor-seco himbacine derivatives inhibit thrombin and cannabinoid CB2 receptors to provide anti-thrombotic and anti-inflammatory activity.

Novel cyclic amine azaheterocyclic carboxamide compounds inhibit p70S6K, resolving poor solubility and bioavailability in cancer treatments.

Factor D inhibitors reduce excessive complement activation and cellular damage in inflammatory disorders.

Fused cyclic compounds with variable substituents demonstrate superior GPR40 receptor agonist activity while maintaining low toxicity and improved stability.

E361G/D362G arrestin-1 variants reduce enolase-1 inhibition to increase ATP levels and photoreceptor survival.

Anti-B7-H5 antibodies modulate immune responses by blocking CD28H interactions, addressing ineffective autoimmune treatments.

KS-513 isolates specific molecular pathways to resolve the trade-off between broad anti-inflammatory action and disease-specific efficacy in COPD treatment.

Segmented heterocyclic derivatives resolve cell permeability and specificity trade-offs by recruiting E3 ligases to degrade MetAP-2.

Transtympanic VEGF inhibitors reduce inner ear edema, alleviating vertigo and hearing loss caused by vascular dysfunction.